Next Plant-Based Unicorn
The plant-based industry has been ignited. Pay close attention to this stock.
Learn more.
Peter Kies, insider at Inovio Pharmaceuticals

Peter Kies Insider Information

Peter Kies is the chief financial officer at Inovio Pharmaceuticals, a role he has held since 2002.

Prior to Inovio, he spent 16 years acquiring experience in functional and strategic management for biotech and high-tech companies spanning the spectrum of corporate growth, ranging from IPO to profitability. 

Kies held the role of CFO for both Genetronics Biomedical Corp. and Newgen Results Corporation. Before that, he worked as the controller for Cytel Corporation and as an auditor for Ernst & Young LLP. 

He earned his B.S. in business administration at United States International University (now Alliant International University) in San Diego.

What is Peter Kies' net worth?

The estimated net worth of Peter Kies is at least $1.42 million as of June 9th, 2021. Mr. Kies owns 164,538 shares of Inovio Pharmaceuticals stock worth more than $1,416,672 as of August 3rd. This net worth estimate does not reflect any other assets that Mr. Kies may own. Additionally, Mr. Kies receives a salary of $653,910.00 as CFO at Inovio Pharmaceuticals.

How old is Peter Kies?

Mr. Kies is currently 58 years old. There are 3 older executives and no younger executives at Inovio Pharmaceuticals.

What is Peter Kies' salary?

As the CFO of Inovio Pharmaceuticals, Inc., Mr. Kies earns $653,910.00 per year. The highest earning executive at Inovio Pharmaceuticals is Dr. J. Joseph Kim, CEO, Pres & Director, who commands a salary of $1,210,000.00 per year.

How do I contact Peter Kies?

The corporate mailing address for Mr. Kies and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at 858-410-3134 and via email at [email protected]

Has Peter Kies been buying or selling shares of Inovio Pharmaceuticals?

Peter Kies has not been actively trading shares of Inovio Pharmaceuticals in the last ninety days. Most recently, Peter Kies sold 33,750 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $10.01, for a transaction totalling $337,837.50. Following the completion of the sale, the chief financial officer now directly owns 164,538 shares of the company's stock, valued at $1,647,025.38.

Who are Inovio Pharmaceuticals' active insiders?

Inovio Pharmaceuticals' insider roster includes Peter Kies (CFO), and Jong Kim (CEO).

Are insiders buying or selling shares of Inovio Pharmaceuticals?

In the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 458,338 shares worth mmore than $5,630,680.22. The most recent insider tranaction occured on June, 09th when Jacqueline Elizabeth Shea COO bought 38,535 shares worth more than $385,735.35. Insiders at Inovio Pharmaceuticals own 2.9 % of the company.

Information on this page was last updated on 6/9/2021.

Peter Kies Insider Trading History at Inovio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/9/2021Sell33,750$10.01$337,837.50164,538View SEC Filing Icon  
6/3/2021Sell10,000$8.03$80,300.00150,788View SEC Filing Icon  
4/21/2021Sell10,000$8.52$85,200.00160,788View SEC Filing Icon  
1/15/2021Sell30,000$10.02$300,600.00149,290View SEC Filing Icon  
12/15/2020Sell20,000$10.69$213,800.00128,040View SEC Filing Icon  
7/15/2020Sell35,000$24.95$873,250.00154,290View SEC Filing Icon  
6/30/2020Sell35,000$26.50$927,500.00119,290View SEC Filing Icon  
11/29/2018Sell10,001$5.28$52,805.2872,089View SEC Filing Icon  
7/10/2018Sell35,000$4.44$155,400.0097,088View SEC Filing Icon  
10/9/2014Buy3,960$10.10$39,996.00View SEC Filing Icon  
See Full Table

Peter Kies Buying and Selling Activity at Inovio Pharmaceuticals

This chart shows Peter Kies's buying and selling at Inovio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals logo
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More

Today's Range

Now: $8.61
Low: $8.44
High: $8.69

50 Day Range

MA: $8.49
Low: $7.04
High: $10.03

2 Week Range

Now: $8.61
Low: $5.81
High: $22.13


2,881,264 shs

Average Volume

10,237,721 shs

Market Capitalization

$1.80 billion

P/E Ratio


Dividend Yield



Next Plant-Based Unicorn
The plant-based industry has been ignited. Pay close attention to this stock.
Learn more.